Immix Biopharma (IMMX) Competitors

Immix Biopharma logo
$7.20 -0.28 (-3.74%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$7.72 +0.52 (+7.21%)
As of 11/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IMMX vs. NAMS, PVLA, SEPN, CLDX, and BHVN

Should you buy Immix Biopharma stock or one of its competitors? Immix Biopharma's main competitors and comparable companies include NewAmsterdam Pharma (NAMS), Palvella Therapeutics (PVLA), Septerna (SEPN), Celldex Therapeutics (CLDX), and Biohaven (BHVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immix Biopharma compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

NewAmsterdam Pharma presently has a consensus target price of $49.82, indicating a potential upside of 156.93%. Immix Biopharma has a consensus target price of $24.14, indicating a potential upside of 235.32%. Given Immix Biopharma's higher probable upside, analysts clearly believe Immix Biopharma is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Immix Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 8 articles in the media. Immix Biopharma's average media sentiment score of 0.61 beat NewAmsterdam Pharma's score of 0.32 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immix Biopharma
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immix Biopharma has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -789.95%. Immix Biopharma's return on equity of -24.93% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma-789.95% -31.39% -28.32%
Immix Biopharma N/A -24.93%-23.55%

Immix Biopharma has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.50M103.35-$203.82M-$1.69N/A
Immix BiopharmaN/AN/A-$29.44M-$0.83N/A

NewAmsterdam Pharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Summary

Immix Biopharma beats NewAmsterdam Pharma on 10 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Palvella Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Palvella Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 9 mentions for Palvella Therapeutics and 8 mentions for Immix Biopharma. Palvella Therapeutics' average media sentiment score of 0.99 beat Immix Biopharma's score of 0.61 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immix Biopharma
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Palvella Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immix Biopharma's return on equity of -24.93% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -24.93% -23.55%
Palvella Therapeutics N/A -44.44%-36.75%

Immix Biopharma currently has a consensus price target of $24.14, indicating a potential upside of 235.32%. Palvella Therapeutics has a consensus price target of $214.86, indicating a potential upside of 48.84%. Given Immix Biopharma's higher possible upside, equities analysts clearly believe Immix Biopharma is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immix Biopharma has higher earnings, but lower revenue than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$29.44M-$0.83N/A
Palvella Therapeutics$42.81M49.30-$41.72M-$5.50N/A

Immix Biopharma has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

Summary

Immix Biopharma and Palvella Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Immix Biopharma compare to Septerna?

Septerna (NASDAQ:SEPN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Septerna has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, Septerna had 14 more articles in the media than Immix Biopharma. MarketBeat recorded 22 mentions for Septerna and 8 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.61 beat Septerna's score of 0.32 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
4 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immix Biopharma
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immix Biopharma has a net margin of 0.00% compared to Septerna's net margin of -61.29%. Septerna's return on equity of -14.98% beat Immix Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-61.29% -14.98% -10.03%
Immix Biopharma N/A -24.93%-23.55%

Immix Biopharma has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$45.95M41.41-$48.88M-$1.29N/A
Immix BiopharmaN/AN/A-$29.44M-$0.83N/A

Septerna currently has a consensus target price of $56.44, suggesting a potential upside of 41.04%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 235.32%. Given Immix Biopharma's higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Immix Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

11.3% of Immix Biopharma shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Immix Biopharma beats Septerna on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Celldex Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Immix Biopharma has higher earnings, but lower revenue than Celldex Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$29.44M-$0.83N/A
Celldex Therapeutics$1.54M1,430.40-$258.76M-$4.30N/A

Immix Biopharma currently has a consensus price target of $24.14, suggesting a potential upside of 235.32%. Celldex Therapeutics has a consensus price target of $64.08, suggesting a potential upside of 128.54%. Given Immix Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Immix Biopharma is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

In the previous week, Immix Biopharma had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for Immix Biopharma and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.93 beat Immix Biopharma's score of 0.61 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immix Biopharma
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immix Biopharma has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Immix Biopharma's return on equity of -24.93% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -24.93% -23.55%
Celldex Therapeutics N/A -52.66%-47.58%

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Immix Biopharma beats Celldex Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to Biohaven?

Biohaven (NYSE:BHVN) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Immix Biopharma's return on equity of -24.93% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
BiohavenN/A -2,271.88% -139.84%
Immix Biopharma N/A -24.93%-23.55%

Biohaven has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Immix Biopharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiohavenN/AN/A-$738.82M-$3.86N/A
Immix BiopharmaN/AN/A-$29.44M-$0.83N/A

Biohaven currently has a consensus target price of $21.14, indicating a potential upside of 59.60%. Immix Biopharma has a consensus target price of $24.14, indicating a potential upside of 235.32%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Biohaven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven
2 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.60
Immix Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

In the previous week, Immix Biopharma had 7 more articles in the media than Biohaven. MarketBeat recorded 8 mentions for Immix Biopharma and 1 mentions for Biohaven. Immix Biopharma's average media sentiment score of 0.61 beat Biohaven's score of -0.65 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biohaven
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Immix Biopharma
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Immix Biopharma beats Biohaven on 10 of the 14 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMMX vs. The Competition

MetricImmix BiopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$626.92M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-8.6725.5633.0126.96
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book1.804.184.463.72
Net Income-$29.44M-$24.15M$3.52B$393.10M
7 Day Performance-16.86%-7.80%-5.94%-5.76%
1 Month Performance-9.77%-5.98%-4.59%-7.14%
1 Year Performance69.41%-8.10%-1.94%-7.46%

Immix Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMX
Immix Biopharma
2.2785 of 5 stars
$7.20
-3.7%
$24.14
+235.3%
+78.2%$626.92MN/AN/A21
NAMS
NewAmsterdam Pharma
3.3622 of 5 stars
$20.72
+8.0%
$49.82
+140.4%
-49.7%$2.48B$25.94MN/A100
PVLA
Palvella Therapeutics
2.5933 of 5 stars
$163.94
-2.8%
$213.85
+30.4%
+76.8%$2.47BN/AN/A29
SEPN
Septerna
2.2737 of 5 stars
$48.56
-7.2%
$56.44
+16.2%
+84.9%$2.44B$96.27MN/A130
CLDX
Celldex Therapeutics
1.8844 of 5 stars
$30.15
-1.6%
$64.08
+112.5%
+7.8%$2.41B$158KN/A198

Related Companies and Tools


This page (NASDAQ:IMMX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners